| CAS号 | 名称 | 物化性质 | 分子式 | 分子量 |
| 213126-92-2 | (±)5(6)-DiHET lactone
(±)5(6)-DiHET lactone ((±)5,6-DiHETrE lactone) | |
C20H32O3 | 320.5 |
| 90906-40-4 | (±)4-HDHA
| |
C22H32O3 | 344.5 |
| 845673-68-9 | (±)4(5)-DiHDPA lactone
| |
C22H32O3 | 344.5 |
| 90906-41-5 | (±)20-HDHA
| |
C22H32O3 | 344.5 |
| 848667-56-1 | (±)2-(14,15-Epoxyeicosatrienoyl) Glycerol
(±)2-(14,15-Epoxyeicosatrienoyl) Glycerol ((±)2-14,15-EG) | |
C23H38O5 | 394.5 |
| 90780-52-2 | (±)17-HDHA MaxSpec® Standard
| |
C22H32O3 | 344.5 |
| 90780-51-1 | (±)16-HDHA
| |
C22H32O3 | 344.5 |
| 88852-33-9 | (±)15-HEPE
| |
C20H30O3 | 318.5 |
| 87042-40-8 | (±)14-HDHA
| |
C22H32O3 | 344.5 |
| 218461-97-3 | (±)14(15)-EET-SI
| |
C21H35NO4S | 397.6 |
| 90780-53-3 | (±)13-HDHA
| |
C22H32O3 | 344.5 |
| 895127-64-7 | (±)13(14)-EpDPA
| |
C22H32O3 | 344.5 |
| 81187-21-5 | (±)12-HEPE
| |
C20H30O3 | 318.5 |
| 263399-35-5 | (±)12(13)-DiHOME
| |
C18H34O4 | 314.5 |
| 73804-65-6 | (±)11-HETE
| |
C20H32O3 | 320.5 |
| 99217-78-4 | (±)11-HEPE
| |
C20H30O3 | 318.5 |
| 5598-37-8 | (±)11-HEDE
| |
C20H36O3 | 324.5 |
| 87018-59-5 | (±)11-HDHA
| |
C22H32O3 | 344.5 |
| 504435-15-8 | (±)11(12)-EpETE
| |
C20H30O3 | 318.5 |
| 867350-92-3 | (±)11(12)-DiHETE
| |
C20H32O4 | 336.5 |
| 90780-50-0 | (±)10-HDHA
| |
C22H32O3 | 344.5 |
| 895127-65-8 | (±)10(11)-EpDPA
| |
C22H32O3 | 344.5 |
| 2123484-71-7 | (±)10(11)-EDP Ethanolamide
| |
C24H37NO3 | 387.6 |
| 1345275-22-0 | (±)10(11)-DiHDPA
| |
C22H34O4 | 362.5 |
| 41680-09-5 | (±)-甘草素
(±)-Liquiritigenin | |
C15H12O4 | 256.26 |
| 18828-58-5 | (±)-丙酰肉碱氯化物
Propionyl-DL-carnitine (chloride) | |
| |
| 1633350-06-7 | (±)-Zanubrutinib ((±)-BGB-3111)
| |
C27H29N5O3 | 471.55 |
| 188048-45-5 | (±)-WS75624B
| |
C18H24N2O5S | 380.46 |
| 23720-86-7 | (±)-Phrymarolin II
| |
C23H22O10 | 458.41 |
| 1216413-74-9 | (±)-Norverapamil-d7 hydrochloride
Norverapamil-d7 hydrochloride | |
C26H30D7ClN2O4 | 484.08 |
| 958293-77-1 | (±)-Naproxen-d3
(±)-Naproxen-d3 (DL-Naproxen-d3) | |
C14H11D3O3 | 233.3 |
| 93879-40-4 | (±)-N-3-苄基萘酚
(+/-)-N-3-Benzylnirvanol | |
| |
| 947316-47-4 | (±)-Duloxetine hydrochloride
| |
C18H20ClNOS | 333.88 |
| 1309793-47-2 | (±)-CPSI-1306
| |
C15H16F2N2O3 | 310.30 |
| 130209-90-4 | (±)-Clopidogrel hydrochloride
| |
C16H16NO2SCl·HCl | 358.28 |
| 55824-09-4 | (±)-Cannabichromeorcin (CRM)
(±)-Cannabichromeorcin (CRM) (CBCO) | |
C17H22O2 | 258.4 |
| 120447-62-3 | (±)-AH5183 hydrochloride
(±)-Vesamicol hydrochloride | |
C17H26ClNO | 295.85 |
| 1464851-21-5 | (Z)-替诺福韦酯杂质
(Z)-9-Propenyladenine ((Z)-Mutagenic Impurity of Tenofovir Disoproxil) | |
C8H9N5 | 175.19 |
| 503065-67-6 | (Z)-5-(3-(Benzyloxy)benzylidene)-2-thioxoimidazolidin-4-one
| |
C17H14N2O2S | 310.37 |
| 1793052-96-6 | (Z)-4-(金刚烷-1-基氨基)-3-((嘧啶-5-基亚甲基)氨基)苯甲酸叔丁酯
(Z)-tert-Butyl 4-(adamantan-1-ylamino)-3-((pyrimidin-5-ylmethylene)amino)benzoate | 密度：1.27±0.1 g/cm3(Predicted)
沸点：614.9±55.0 °C(Predicted)
|
C26H32N4O2 | 432.56 |
| 283159-94-4 | (S,S)-Valifenalate ((S,S)-IR5885)
| |
C19H27ClN2O5 | 398.88 |
| 2172820-09-4 | (S,R,S)-AHPC-PEG2-acid
| |
C30H42N4O8S | 618.74 |
| 2245697-83-8 | (S,R,S)-AHPC-C3-NH2 (VH032-C3-NH2)
| |
C27H40ClN5O4S | 566.16 |
| 2361119-88-0 | (S,R,S)-AHPC-C3-NH2
| |
C26H37N5O4S | 515.67 |
| 2341796-75-4 | (S,R,S)-AHPC-C10-NH2 dihydrochloride
| |
C33H53Cl2N5O4S | 686.78 |
| 2341796-74-3 | (S,R,S)-AHPC-C10-NH2
| |
C33H51N5O4S | 613.85 |
| 66635-92-5 | (S)-酮咯酸
(S)-Ketorolac | |
C15H13NO3 | 255.27 |
| 1431699-67-0 | (S)-特地唑胺
(S)-Tedizolid | |
C17H15FN6O3 | 370.34 |
| 1443448-82-5 | (S)-β-水杨酰氨基-a-外甲基-γ-丁内酯
(S)-β-Salicyloylamino-a-exo-methylene-γ-butyrolactone | 密度：1.36±0.1 g/cm3(Predicted)
沸点：536.7±50.0 °C(Predicted)
|
C12H11NO4 | 233.22 |
| 856925-75-2 | (S)-nitro-Blebbistatin
(S)-nitro-Blebbistatin (S-(−)-7-Desmethyl-8-nitro Blebbistatin) | |
C17H13N3O4 | 323.3 |
